Sign in
WithdrawnPhase 2

Trifecta Research Study

Key facts

Who runs it
Johns Hopkins University
Where
Baltimore, United StatesSee the site
Trial code
Status
Withdrawn
Phase
Phase 2
Started
Sept 2025
Expected to end
Dec 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Hormone Replacement Therapy (HRT)
  • Magnetic Resonance Therapy (MeRT)
  • ibogaine with magnesium treatment
  • 5-MeO-DMT
Record updated
22 August 2025
Why it stopped
Study is being conducted externally.

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • At least 18 years of age
  • Sponsored by SOC-F Program

Who cannot take part

  • Refusal to taper off of selective serotonin reuptake inhibitor (SSRI) medication
  • Diagnosis of Schizophrenia, Bipolar I or II disorder for which patient has been hospitalized or medicated, Depersonalization and/or Derealization Disorder
  • Cerebellar dysfunction, Epilepsy, Psychosis or acute confusional state, Dementia
  • History of heart failure or hypertrophic heart
  • Active blood clots (e.g., Pulmonary embolism, Deep vein thrombosis)
  • Major respiratory conditions (e.g., Emphysema, Cystic fibrosis)
  • Severe chronic gastrointestinal issues (e.g., bleeding ulcer, leaky gut syndrome)
  • Prolonged corrected QT interval (QTc) Interval (450ms in males; 470ms in females)
  • Abnormal blood test results (e.g., potassium or magnesium outside normal range)
  • Within 6 months of surgeries
  • Impaired kidney or liver function

Where in United States

  • Johns Hopkins Center for Psychedelic and Consciousness ResearchBaltimore, United States

About the trial

What the trial wants to find out

The Special Operations Care-Fund (SOC-F) will sponsor the application of four treatments - hormone replacement, magnetic resonance brain stimulation, ibogaine, and 5-Meo-DMT - to Special Operations Forces veterans with a history of combat deployments, traumatic brain injury, and problems with mental health and cognitive functioning. An observational study will be conducted in parallel by the Johns Hopkins Center for Psychedelic and Consciousness Research to determine the effectiveness and safety of each treatment, primarily through measuring post-treatment changes in PTSD symptoms and cognitive functioning.

The 2 groups in the trial

  • Individuals in this arm will undergo HRT, then Ibogaine and 5-MeO treatment, and then MeRT therapy.Treatment being tested

    Treatment: Hormone Replacement Therapy (HRT), Magnetic Resonance Therapy (MeRT), ibogaine with magnesium treatment, and 5-MeO-DMT

  • Individuals in this arm will undergo HRT, then MeRT therapy, and then Ibogaine and 5-MeO-DMT.Existing treatment, for comparison

    Treatment: Hormone Replacement Therapy (HRT), Magnetic Resonance Therapy (MeRT), ibogaine with magnesium treatment, and 5-MeO-DMT

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Trifecta Research Study: Examining Hormone Replacement Therapy, Magnetic e-Resonance Therapy, Ibogaine, and 5-MeO-DMT in the Treatment of Posttraumatic Stress Disorder and Traumatic Brain Injury-related Cognitive Symptoms
Record updated
22 August 2025